Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “Sutro Biopharma” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 10
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 10 pipeline programs matching "Sutro Biopharma" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

10 results for “Sutro Biopharma” Back to intelligence hub

Search results

  1. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial
  2. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial
  3. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Lung Cancer

    phase 2 small molecule terminated

    1 trial
  4. REFRaME-P1

    SUTRO BIOPHARMA, INC.

    Acute Myeloid Leukemia (AML)

    phase 2 other active

    1 trial
  5. STRO-002

    SUTRO BIOPHARMA, INC.

    Neoplasm Malignant

    phase 2 mab completed

    1 trial
  6. STRO-002-GM3

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 2 small molecule active

    1 trial
  7. STRO-001

    SUTRO BIOPHARMA, INC.

    B-cell Lymphoma

    phase 1 small molecule completed

    1 trial
  8. STRO-002

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    2 trials
  9. STRO-002-GM2

    SUTRO BIOPHARMA, INC.

    Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)

    phase 1 other active

    1 trial
  10. STRO-004

    SUTRO BIOPHARMA, INC.

    Head and Neck Squamous Cell Carcinoma HNSCC

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.